Jcar017 (Lisocabtagene Maraleucel)
Immunoproliferative Disorders
Juno Therapeutics, a Subsidiary of CelgeneCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Immunoproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
Ibrutinib Oncternal Therapeutics, Inc | Phase 3 | B |
Tucidinostat Fudan University | Phase 2 | CCC |
Oricar-017 OriCell Therapeutics Co., Ltd. | Phase 1 | CC |
Fludarabine UNC Lineberger Comprehensive Cancer Center | Phase 1 | CC |
View all 12 →
Same molecule, other indications
Jcar017 (Lisocabtagene Maraleucel) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →